What is XCUR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XCUR?

P/E (TTM) is n/a and 52-week range is $0.99 to $9.48 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XCUR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XCUR?

The company profile lists revenue (TTM) near $707K, net income (TTM) near $-117M, EPS (TTM) near $-1.30 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Exicure Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Chicago, Illinois, US, 6.4M shares outstanding, ISIN US30205M3097 when available from company profile and filing metadata.

Exicure Inc

$XCUR

Health Care · Biotechnology

IR Run Scenarios

$1.05

+5.00%

Exicure Inc

$XCUR

Health Care · Biotechnology

IR Run Scenarios

$1.05

+5.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.

Employees

8

Website

www.exicuretx.com/

IPO

2018-05-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US30205M3097

Headquarters

Chicago, Illinois, US

Shares outstanding

6.4M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

2.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.

Employees

8

Website

www.exicuretx.com/

IPO

2018-05-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)